Skip to main content

Table 2 Local-regional progression-free survival in 120 stage IV NSCLC patients according to responses of primary tumors

From: Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Variable No. Survival rate (%) Median survival time (months) 95% confidence interval χ 2 p
1 year 2 year 3 year 5 year
CR 11 63.6 42.4 31.8 31.8 20 8.5 31.5 2.065 0.356
PR 91 58.3 27.5 18.3 0 15 11.5 18.5
SD 18 50.0 35.7 26.8 26.8 10 1.9 18.1
CR 11 63.6 42.4 31.8 31.8 20 8.5 31.5 1.922 0.166
PR + SD 109 56.9 29.0 19.7 7.8 15 11.9 18.1